Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of three new StarBright™ Red Dyes—StarBright ...
Aug 1 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.
CEO Norman Schwartz noted that despite macroeconomic headwinds, the company is focusing on long-term opportunities in life science research and diagnostics markets. Schwartz emphasized Bio-Rad's ...
Chief Operating Officer Jon DiVincenzo stated that Bio-Rad met its revised 2024 guidance for revenue and operating margin, achieving gross margin expansion through manufacturing productivity ...
HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported second-quarter net income of $317.8 million, after reporting a loss in the same period a year ...
HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a year earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback